Journey MedicalDERM
DERM
About: Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
Employees: 58
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
21% more capital invested
Capital invested by funds: $12.2M [Q3] → $14.8M (+$2.6M) [Q4]
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
10.74% more ownership
Funds ownership: 14.65% [Q3] → 25.39% (+10.74%) [Q4]
3% more funds holding
Funds holding: 36 [Q3] → 37 (+1) [Q4]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for DERM.
Financial journalist opinion
Based on 8 articles about DERM published over the past 30 days
Neutral
Seeking Alpha
1 day ago
Journey Medical Corporation (DERM) Q4 2024 Earnings Call Transcript
Journey Medical Corporation (NASDAQ:DERM ) Q4 2024 Results Conference Call March 26, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and CEO Joseph Benesch - Chief Financial Officer Louis Donati - Director of Market Access Srini Sidgiddi - Vice President, Research and Development Ramsey Alloush - General Counsel and Corporate Secretary Conference Call Participants Thomas Flaten - Lake Street Capital Markets Scott Henry - AGP Brandon Folkes - Rodman & Renshaw Jason Wittes - Roth Capital Kalpit Patel - B. Riley Securities Operator Ladies and gentlemen, thank you for standing by.
Positive
Zacks Investment Research
1 day ago
Journey Medical Corporation (DERM) Tops Q4 Earnings Estimates
Journey Medical Corporation (DERM) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to loss of $0.12 per share a year ago.
Neutral
GlobeNewsWire
1 day ago
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended December 31, 2024 were $56.1 million Met All Financial Guidance for 2024 Emrosi Phase 3 Clinical Trial Results Published in JAMA Dermatology Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz.
Neutral
GlobeNewsWire
4 days ago
Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
Initial distribution of Emrosi to pharmacies ongoing First prescriptions of Emrosi filled SCOTTSDALE, Ariz., March 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the launch of and the first prescriptions filled for Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the treatment of inflammatory lesions of rosacea in adults.
Neutral
GlobeNewsWire
1 week ago
Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025
Company to host conference call to discuss financial results and provide a corporate update on March 26, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on March 26, 2025 at 4:30 p.m. ET
Neutral
GlobeNewsWire
2 weeks ago
Journey Medical Corporation to Participate in the 37th Annual ROTH Conference
SCOTTSDALE, Ariz., March 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that management will participate in the 37th Annual ROTH Conference, which is being held March 16-18, 2025 in Dana Point, California.
Neutral
GlobeNewsWire
3 weeks ago
Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea
DFD-29 (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) achieved the co-primary and all secondary endpoints with no significant safety issues when administered once daily for 16 weeks
Neutral
GlobeNewsWire
3 weeks ago
Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida
U.S. FDA approved Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the treatment of inflammatory lesions of rosacea in adults in November 2024 U.S. FDA approved Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the treatment of inflammatory lesions of rosacea in adults in November 2024
Positive
Seeking Alpha
1 month ago
Stock Picks From Seeking Alpha's January 2025 New Analysts
In January, Seeking Alpha welcomed 29 new analysts. This article introduces them and showcases some of their top picks. Analysts highlighted include The Conservative Investor recommending Dassault Aviation, Christopher Gray on ASML Holding, and Inflexio Research on Bragg Gaming Group, all rated as Buys. Analysts' diverse backgrounds span sectors like technology, finance, and consumer staples, with investment strategies focusing on value, growth, and special situations.
Positive
Seeking Alpha
1 month ago
Journey Medical Corporation: Emrosi's Launch Could Be A Turning Point
Journey Medical's future hinges on Emrosi™, a new formulation of minocycline for rosacea, showing superior efficacy over Oracea® in Phase III trials. Despite current financial challenges and a need for additional funding, Emrosi's market exclusivity until 2039 and strong trial results offer significant potential. Dermatologists' acceptance and PBM positioning are crucial for Emrosi's success, given its proven efficacy and potential to replace Oracea.
Charts implemented using Lightweight Charts™